NCT06599502 2026-03-18
ALAFOSS-01
AstraZeneca
Phase 1 Terminated
Clinical Trials
38 trialsNCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05743036 2025-08-08
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Terminated
NCT05619172 2025-07-24
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
Phase 2 Terminated
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT04853043 2025-05-06
APK Mutant
University of Utah
Phase 2 Terminated
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04515394 2022-12-22
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT02117466 2021-04-14
IMPACT-CRC
Amsterdam UMC, location VUmc
Phase 1/2 Terminated
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT01317433 2020-03-25
SKINUX
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT00541112 2020-02-11
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase 2 Terminated
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT01871311 2019-02-08
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
Phase 1 Terminated
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT01925274 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00077233 2018-05-16
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01309126 2017-07-13
PRIMUS
HiberCell, Inc.
Phase 3 Terminated
NCT01134666 2017-06-09
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany
Terminated
NCT00361244 2017-02-17
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT01718808 2017-01-24
Cetuximab for Elderly Patients With mCRC
Swiss Cancer Institute
Phase 2 Terminated
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01060423 2016-10-26
DEBIRITUX
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01858662 2016-04-15
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT00271011 2015-12-03
A Study of Mitomycin C, Irinotecan, and Cetuximab
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01004159 2015-10-19
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00538291 2014-08-28
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
City of Hope Medical Center
Phase 2 Terminated
NCT01074333 2014-06-17
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Terminated
NCT00719199 2013-10-22
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
EMD Serono
Phase 1 Terminated
NCT00531115 2013-02-20
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Terminated
NCT00681876 2013-02-13
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00251186 2010-01-26
First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00327093 2009-02-09
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
Hospices Civils de Lyon
Phase 4 Terminated